Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04074785
Recruitment Status : Recruiting
First Posted : August 30, 2019
Last Update Posted : December 16, 2020
Sponsor:
Information provided by (Responsible Party):
Edward Pan, University of Texas Southwestern Medical Center

Tracking Information
First Submitted Date  ICMJE August 28, 2019
First Posted Date  ICMJE August 30, 2019
Last Update Posted Date December 16, 2020
Actual Study Start Date  ICMJE December 13, 2019
Estimated Primary Completion Date October 24, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 11, 2020)
Number of participants with adverse event [ Time Frame: upto 2 years after study treatment ]
Assess safety and adverse events associated with Abemaciclib 150 mg orally twice daily when administered with Bevacizumab 10 mg/kg intravenously every 2 weeks to recurrent GBM patients with specific tumor molecular aberrations. NCI Common terminology criteria for adverse events (CTCAE v.5) will be used to assess the adverse events.
Original Primary Outcome Measures  ICMJE
 (submitted: August 28, 2019)
Safety [ Time Frame: 2 years ]
Assess safety and adverse events associated with Abemaciclib 150 mg orally twice daily when administered with Bevacizumab 10 mg/kg intravenously every 2 weeks to recurrent GBM patients with specific tumor molecular aberrations
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 11, 2020)
  • Median Overall Survival [ Time Frame: upto 2 years after study treatment ]
    Median OS of the study patients from time of study entry until death or lost to follow-up.
  • Median Progression Free Survival [ Time Frame: upto 2 years after study treatment ]
    Median PFS of the study patients from time of study entry until progression as determined by the Response Assessment in Neuro-Oncology (RANO) criteria [30].
Original Secondary Outcome Measures  ICMJE
 (submitted: August 28, 2019)
  • Overall Survival [ Time Frame: 2 years ]
    To determine the median OS of the study patients from time of study entry until death or lost to follow-up.
  • Progression Free Survival [ Time Frame: 2 years ]
    To determine the median PFS of the study patients from time of study entry until progression as determined by the Response Assessment in Neuro-Oncology (RANO) criteria [30].
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6
Official Title  ICMJE Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6
Brief Summary Describe the safety and adverse events associated with Abemaciclib 150 mg orally twice daily when administered with Bevacizumab 10 mg/kg intravenously every 2 weeks to recurrent GBM patients with specific tumor molecular aberrations
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Early Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • GBM
  • Glioblastoma
  • Brain Tumor
  • Brain Tumor, Recurrent
Intervention  ICMJE
  • Drug: Abemaciclib
    Abemaciclib 150 mg po bid
    Other Name: Verzenio
  • Drug: Bevacizumab
    Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
    Other Name: Avastin
Study Arms  ICMJE
  • Experimental: Safety Run-In
    Abemaciclib 150 mg po bid PLUS Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
    Interventions:
    • Drug: Abemaciclib
    • Drug: Bevacizumab
  • Experimental: Abemaciclib with Bevacizumab
    Abemaciclib 100 mg po bid PLUS Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
    Interventions:
    • Drug: Abemaciclib
    • Drug: Bevacizumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: August 28, 2019)
10
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE October 24, 2022
Estimated Primary Completion Date October 24, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically confirmed GBM at first or second recurrence after concurrent chemoradiotherapy. Patients with an initial diagnosis of a lower-grade glioma are eligible if a subsequent biopsy was determined to be GBM. GBMs either from the initial resection or at repeat resection at recurrence must be analyzed by next-generation exome sequencing (NES) and RNA-sequencing and must have the following aberrations:
  • Heterozygous or homozygous loss of CDKN2A and/or CDKN2B

OR

  • Gain or amplification of CDK4 and/or 6

NOTE: Patients with GBMs having loss of function of RB1 are EXCLUDED.

  • Imaging confirmation of first tumor progression or regrowth as defined by the RANO criteria. A minimum of 12 weeks must have elapsed from the completion of radiotherapy to study entry to minimize the potential for magnetic resonance imaging (MRI) changes related to radiation necrosis that might be misdiagnosed as progression of disease, unless there is a new lesion outside the radiation field or unequivocal evidence of viable tumor on histopathological sampling.
  • Karnofsky performance status (KPS) ≥ 60%.
  • Stable or decreasing dose of corticosteroids within 5 days prior to randomization.
  • For women who are of child-bearing potential or surgically sterile (absence of ovaries and/or uterus) and who are sexually active: to use an adequate method of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly) during the treatment period and for at least 6 months after last dose of study drug. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

For male patients who are partners of premenopausal women: agreement to use a barrier method of contraception during the treatment period and for at least 6 months after the last dose of study drug.

  • A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  • Patients who have undergone recent surgery for recurrent or progressive tumor are eligible provided that:
  • Surgery must have confirmed the recurrence.
  • A minimum of 28 days must have elapsed from the day of surgery to study entry. For core or needle biopsy, a minimum of 7 days must have elapsed prior to study entry.
  • Craniotomy or intracranial biopsy site must be adequately healed and free of drainage or cellulitis, and the underlying cranioplasty must appear intact at the time of randomization.
  • Patients must be willing and able to provide written informed consent and to comply with the study protocol as judged by the investigator.
  • Age ≥ 18 years.
  • Patients must have recovered (Common Terminology Criteria for Adverse Events CTCAE] Grade ≤1) from the acute effects of chemotherapy prior to study entry. Minimum times from prior therapies include:
  • ≥ 28 days elapsed from the administration of any investigational agent
  • ≥ 28 days elapsed from the administration of any prior cytotoxic agents, except ≥ 42 days from nitrosoureas

NOTE: Prior treatment with Novo-TTF therapy is allowed at initial diagnosis, but must be discontinued prior to study entry.

  • Patients must be able to swallow oral medications.
  • Ability to understand and the willingness to sign a written informed consent.
  • Patients must have adequate organ and marrow function

Exclusion Criteria:

  • Prior treatment with Bevacizumab, Abemaciclib, or any other CDK4/6 inhibitor or other systemic VEGF- or VEGF-receptor-targeted agent.
  • Prior treatment with prolifeprospan 20 with carmustine wafer.
  • Evidence of recent hemorrhage on baseline MRI of the brain. However, patients with clinically asymptomatic presence of hemosiderin, resolving hemorrhagic changes related to surgery, or presence of punctuate hemorrhage in the tumor are eligible.
  • Concurrent investigational agents.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Agent(s) or other agents used in study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
  • Patients unable to undergo brain MRI scans with IV gadolinium.
  • Screening laboratory values outside of the values listed on Table 2.
  • Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg while on antihypertensive medication).
  • Uncontrolled diabetes despite maximal medical management.
  • Prior history of hypertensive crisis or hypertensive encephalopathy.
  • New York Heart Association Grade II or greater congestive cardiac failure.
  • History of myocardial infarction (within 12 months) or unstable angina (within 6 months) prior to study entry.
  • History of stroke or transient ischemic attacks within 6 months prior to study entry.
  • Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to study entry.
  • Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).
  • History of abdominal fistula or gastrointestinal perforation within 6 months prior to study entry.
  • History of intracranial abscess within 6 months prior to randomization or active bacterial infection (requiring intravenous [IV] antibiotics within 2 weeks from initiation of study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive].
  • Serious non-healing wound, active ulcer, or untreated bone fracture.
  • History of another malignancy in the previous 3 years, with a disease-free interval of < 3 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are ELIGIBLE.
  • Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibody.
  • Taking any treatments listed in the Prohibited Concomitant Medications.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 99 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Shanda Grant 214-648-7097 shanda.grant@utsouthwestern.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04074785
Other Study ID Numbers  ICMJE SCCC-06319; STU-2019-1214
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Edward Pan, University of Texas Southwestern Medical Center
Study Sponsor  ICMJE Edward Pan
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account University of Texas Southwestern Medical Center
Verification Date December 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP